Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder.

Biomolecules - 10 Oct 2021

Castaldelli-Maia João M, Malbergier André, de Oliveira Adriana B P, Amaral Ricardo A, Negrão André B, Gonçalves Priscila D, Ventriglio Antonio, de Berardis Domenico, de Antonio Juliana, Firigato Isabela, Gattás Gilka J F, de Toledo Gonçalves Fernanda

Abstract excerpt

Background: The efficacy of naltrexone in the treatment of alcohol use disorder (AUD) has been associated with a set of variables not directly related with the expression of opioid receptors. All the variables have been found to be highly associated with AUD itself or more severe clinical levels of AUD. Objectives: Given the high association between alcohol metabolizing enzymes (AME) and the outcome of AUD, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Ethanol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Genotype

Share to Naltrexone

Share to Polymorphism, Single Nucleotide

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 34680127
DOI: 10.3390/biom11101495
PMCID: PMC8533258

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder.PMID 34680127Read ↗

A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder.Semantic proximity Read ↗

Opioid pharmacogenetics of alcohol addiction.Semantic proximity Read ↗

Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.Semantic proximity Read ↗

Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.Semantic proximity Read ↗

Pharmacogenetically driven treatments for alcoholism: are we there yet?Semantic proximity Read ↗

Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.Semantic proximity Read ↗

Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.Semantic proximity Read ↗

Alcoholism: genes and mechanismsSemantic proximity Read ↗

Advances in Medications and Tailoring Treatment for Alcohol Use DisorderSemantic proximity Read ↗

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.Semantic proximity Read ↗

OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation.Semantic proximity Read ↗

Pharmacogenetic treatments for drug addiction: alcohol and opiates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.